Our study demonstrated high potency of ATM-AVI (MIC90 0.25–1 μg/mL) against MDR Enterobacterales, with ≥98.5% and ≥99.1% isolates, from wards and infection sources, respectively, inhibited at the tentative breakpoint of ≤8 μg/mL globally and in all regions. This evidence concerns the gene ATM and infection.